Panobinostat Combo Shows Early Promise in Myelofibrosis and Polycythemia Vera
February 21st 2020The combination of panobinostat and ruxolitinib demonstrated efficacy and a tolerable safety profile as a treatment for patients with primary myelofibrosis and post-polycythemia vera–related myelofibrosis and post essential thrombocythemia–related myelofibrosis.
Read More
Ruxolitinib Combo Elicits Clinical Activity in Polycythemia Vera and Myelofibrosis
January 30th 2020The combination of ruxolitinib (Jakafi) plus low-dose pegylated interferon-a2 demonstrated an improvement in peripheral blood cell counts bone marrow cellularity and fibrosis, and symptom burden with acceptable toxicity in patients with polycythemia vera or proliferative myelofibrosis.
Read More
Kopetz Highlights Improved QoL, Efficacy With Encorafenib Regimens in BRAF+ mCRC
January 25th 2020Scott Kopetz, MD, PhD, FACP, sheds light on encorafenib triplet and doublet options for patients with BRAF V600E–mutant metastatic colorectal cancer and other novel regimens under investigation.
Read More
Nivolumab Triplet Elicits Clinically Meaningful Responses in Advanced HCC
January 25th 2020The triplet regimen of nivolumab (Opdivo), ipilimumab (Yervoy), and cabozantinib (Cabometyx) achieved clinically meaningful responses in patients with advanced hepatocellular carcinoma who were either sorafenib (Nexavar)-naïve, or resistant to or intolerant of sorafenib.
Read More